E. J. Fritch

Efficacy of Host Cell Serine Protease Inhibitor MM3122 against SARS-CoV-2 for Treatment and Prevention of COVID-19

This paper demonstrates that MM3122, a host cell serine protease inhibitor, effectively inhibits SARS-CoV-2 replication and reduces disease severity in mice, both prophylactically and therapeutically.

A model of persistent post SARS-CoV-2 induced lung disease for target identification and testing of therapeutic strategies

This paper develops a murine model of persistent post-SARS-CoV-2 lung disease to identify therapeutic targets and test interventions for PASC.

Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice

This study tests FDA-approved kinase inhibitors against SARS-CoV-2 in vitro and in vivo, finding that vandetanib reduces inflammatory cytokines and mitigates lung inflammation in infected mice without reducing viral load.

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms

This study evaluates the in vitro antiviral activity of three Ebola and Marburg virus inhibitors against SARS-CoV-2 and explores their potential mechanisms of action.

Comparative analysis of coronavirus genomic RNA structure reveals conservation in SARS-like coronaviruses

This study identifies conserved RNA secondary structures in SARS-like coronaviruses, suggesting their role in replication and pathogenesis and proposing their disruption as a vaccine strategy.

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

This paper describes the development of an mRNA vaccine (mRNA-1273) against SARS-CoV-2, showing it induces neutralizing antibodies and CD8 T cell responses and protects mice from infection.

Zika virus infection in Collaborative Cross mice

The paper tests Collaborative Cross mice as an immune-competent model for ZIKV infection, finding poor infection and low antibody response.